VCFix® Spinal System
VCFix is Amber’s flagship vertebral reconstruction system, designed to restore vertebral body anatomy and support load-bearing function in defined vertebral fracture patients.
VCFix® is an innovative implant for vertebral body augmentation developed by Amber Implants. We designed this product for the treatment of vertebral compression fractures. The product, consisting of a preparation, implantation, and an optional supplementary fixation kit, is intended to be used to treat and reduce compression fractures in vertebrae that have collapsed due to trauma, tumor, or degenerative diseases.
The VCFix® Spinal System provides internal support and is currently intended for use with cleared bone cement in the U.S., with Amber continuing to evaluate expanded treatment strategies as evidence and indications evolve.
VCFix helps clinicians address the biomechanical needs of vertebral fractures—moving beyond void filling alone toward anatomic restoration, three-column support, and procedural flexibility.
VCFix®: Improving the treatment of spinal fracture
Three-Column Support
Efficient Minimally Invasive Workflow
Load-Bearing Restoration
Controlled Anatomic Restoration
VCFix® is available in multiple implant sizes and features an adjustable angular expansion mechanism, supporting controlled fracture reduction and patient-specific anatomic restoration.
Inducing Osseointegration
Due to its optimized perforated structure and appropriate mechanical properties, VCFix® offers an ideal bone-implant interface.
Stand-alone
Device
Controlled
Anatomic Restoration
VCFix® is available in multiple implant sizes and features an adjustable angular expansion mechanism, supporting controlled fracture reduction and patient-specific anatomic restoration.
Enhanced
Stabilization
VCFix® System Timeline
Idea generation and patent protection.
VCFix® advanced through early feasibility work and project planning, establishing the foundation for subsequent product development and regulatory engagement.
VCFix® Spinal System receives Breakthrough Device Designation from the U.S. FDA, supporting priority review during development.

Company successfully completes the First-in-Human clinical trials, including follow-up. (For more information, see the news item.)

Company receives approval from both the Ethics Committee (EC) and BfArM in Germany for pivotal EXPAND study of the VCFix® Spinal System.

Introduction of VCFix® Spinal System with cement in the US market.
The product information described on this page is specific to . Switch to your country of preference to view the relevant information for that region.